Performance status score: do patients and their oncologists agree?

被引:162
作者
Blagden, SP
Charman, SC
Sharples, LD
Magee, LRA
Gilligan, D
机构
[1] Addenbrookes Hosp, Dept Oncol, Cambridge CB2 2QQ, England
[2] Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England
[3] Papworth Hosp, Thorac Oncol Unit, Cambridge CB3 8RE, England
关键词
ECOG; performance status; lung cancer; oncologist; prognosis;
D O I
10.1038/sj.bjc.6601231
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oncologists traditionally assess their patients' ECOG performance status ( PS), and few studies have evaluated the accuracy of these assessments. In this study, 101 patients attending a rapid access clinic at Papworth Hospital with a diagnosis of lung cancer were asked to assess their own ECOG PS score on a scale between 0 and 4. Patients' scores were compared to the PS assessment of them made by their oncologists. Of 98 patients with primary non-small-cell lung cancer ( NSCLC) and small-cell lung cancer (SCLC), weighted kappa statistics showed PS score agreement between patient and oncologist of 0.45. Both patient- and oncologist-assessed scores reflected survival duration ( in NSCLC and SCLC) as well as disease stage ( in NSCLC), with oncologist-assessed scores being only marginally more predictive of survival. There was no sex difference in patient assessment of PS scores, but oncologists scored female patients more pessimistically than males. This study showed that, with few exceptions, patients and oncologists assessed PS scores similarly. Although oncologists should continue to score PS objectively, it may benefit their clinical practice to involve their patients in these assessments.
引用
收藏
页码:1022 / 1027
页数:6
相关论文
共 25 条
[1]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[2]   Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer [J].
Ando, M ;
Ando, Y ;
Hasegawa, Y ;
Shimokata, K ;
Minami, H ;
Wakai, K ;
Ohno, Y ;
Sakai, S .
BRITISH JOURNAL OF CANCER, 2001, 85 (11) :1634-1639
[3]   Prognostic factors in non-small cell lung cancer - A decade of progress [J].
Brundage, MD ;
Davies, D ;
Mackillop, WJ .
CHEST, 2002, 122 (03) :1037-1057
[4]   Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution [J].
Buccheri, G ;
Ferrigno, D ;
Tamburini, M .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (07) :1135-1141
[5]   Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why? [J].
Bunn, PA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :23S-33S
[6]   PERFORMANCE AND PROGNOSIS IN PATIENTS WITH LUNG-CANCER [J].
CAPEWELL, S ;
SUDLOW, MF .
THORAX, 1990, 45 (12) :951-956
[7]   A PILOT-STUDY OF THE FUNCTIONAL LIVING INDEX - CANCER (FLIC) SCALE FOR THE ASSESSMENT OF QUALITY OF LIFE FOR METASTATIC LUNG-CANCER PATIENTS [J].
FINKELSTEIN, DM ;
CASSILETH, BR ;
BONOMI, PD ;
RUCKDESCHEL, JC ;
EZDINLI, EZ ;
WOLTER, JM .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (06) :630-633
[8]   Comorbidity and karnofksy performance score are independent prognostic factors in Stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies [J].
Firat, S ;
Byhardt, RW ;
Gore, E .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (02) :357-364
[9]   CAN ONCOLOGISTS DETECT DISTRESS IN THEIR OUT-PATIENTS AND HOW SATISFIED ARE THEY WITH THEIR PERFORMANCE DURING HAD NEWS CONSULTATIONS [J].
FORD, S ;
FALLOWFIELD, L ;
LEWIS, S .
BRITISH JOURNAL OF CANCER, 1994, 70 (04) :767-770
[10]   Depression in patients with lung cancer: Prevalence and risk factors derived from quality-of-life data [J].
Hopwood, P ;
Stephens, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :893-903